CPH:CA:TSX-Cipher Pharmaceuticals Inc (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

CAD 14.72

Change

+0.08 (+0.55)%

Market Cap

CAD 0.38B

Volume

0.03M

Analyst Target

CAD 1.42
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
BHC:CA Bausch Health Companies Inc

-0.01 (-0.09%)

CAD 3.94B
TLRY:CA Tilray Inc

-0.12 (-5.69%)

CAD 1.89B
CURA:CA Curaleaf Holdings Inc.

-0.17 (-7.42%)

CAD 1.61B
CRON:CA Cronos Group Inc

+0.01 (+0.35%)

CAD 1.07B
DHT-UN:CA DRI Healthcare Trust

-0.33 (-2.64%)

CAD 0.75B
WEED:CA Canopy Growth Corp

-0.28 (-6.78%)

CAD 0.60B
AOV:CA Amotiv Limited

+0.01 (+0.18%)

CAD 0.58B
GUD:CA Knight Therapeutics Inc.

+0.01 (+0.18%)

CAD 0.58B
DHT-U:CA DRI Healthcare Trust

+0.25 (+3.03%)

CAD 0.54B
ACB:CA Aurora Cannabis Inc

-0.29 (-4.34%)

CAD 0.36B

ETFs Containing CPH:CA

NVIR Listed Funds Trust - Hori.. 3.91 % 0.00 %

-0.02 (-0.07%)

N/A
AUCO:LSE L&G Gold Mining UCITS ETF 0.00 % 0.00 %

+0.40 (+-0.07%)

N/A
AUCP:LSE Legal & General UCITS ETF.. 0.00 % 0.00 %

+75.50 (+-0.07%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.79% 45% F 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.79% 45% F 84% B
Trailing 12 Months  
Capital Gain 147.81% 95% A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 147.81% 95% A 98% N/A
Trailing 5 Years  
Capital Gain 1,087.10% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,087.10% 100% F 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 88.74% 95% A 96% N/A
Dividend Return 88.74% 95% A 96% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 68.99% 36% F 13% F
Risk Adjusted Return 128.63% 100% F 99% N/A
Market Capitalization 0.38B 61% D- 55% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector